Increasing mtDNA levels as therapy for mitochondrial optic neuropathies.

Area of Science:

• Ophthalmology
• Mitochondrial Medicine
• Neuroscience

Background:

• Leber hereditary optic neuropathy (LHON) is an inherited mitochondrial optic neuropathy with no effective treatments.
• Primary open-angle glaucoma (POAG) is a common acquired optic neuropathy, and current treatments to slow progression are inadequate.
• Emerging evidence suggests POAG may also be a mitochondrial optic neuropathy (MON).

Purpose of the Study:

• To explore the shared molecular mechanisms between LHON and POAG.
• To propose novel therapeutic strategies for mitochondrial optic neuropathies (MONs).

Main Methods:

• Review of existing literature on LHON, POAG, and mitochondrial dysfunction.
• Analysis of common risk factors and their impact on mitochondrial DNA (mtDNA) content.
• Identification of potential therapeutic targets based on molecular mechanisms.

Main Results:

• Both LHON and POAG share common risk factors that decrease mitochondrial (mt)DNA content.
• These shared factors suggest a common underlying mitochondrial pathophysiology.
• Pharmacological interventions targeting mitochondrial function are plausible.

Conclusions:

• POAG may be classified as a mitochondrial optic neuropathy (MON).
• Therapies aimed at increasing mtDNA levels and oxidative phosphorylation (OXPHOS) capability could offer new treatment avenues.
• Targeting mitochondrial energy production presents a promising approach for treating both LHON and POAG.